Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi BiotechnologyfiledCriticalRegeneron Pharma
Priority claimed from PCT/US2017/021149external-prioritypatent/WO2017155990A1/en
Publication of MA43465A1publicationCriticalpatent/MA43465A1/en
Publication of MA43465B2publicationCriticalpatent/MA43465B2/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La présente invention concerne l'utilisation d'un anticorps du récepteur anti-il6 en monothérapie pour le traitement de la polyarthrite rhumatoïde et pour l'amélioration de la fonction physique et de la qualité de vie d'un sujet souffrant de polyarthrite rhumatoïde.The present invention relates to the use of an anti-il6 receptor antibody as monotherapy for the treatment of rheumatoid arthritis and for the improvement of the physical function and quality of life of a subject suffering from rheumatoid arthritis.
MA43465A2016-05-202017-03-07
Compositions and methods for treating rheumatoid arthritis
MA43465B2
(en)